INTRODUCTION {#SEC1}
============

Identifying molecular alterations that happen early in carcinogenesis, known as field defects, is important for early cancer detection. One common approach is to compare normal tissue of healthy individuals to normal tissue adjacent to tumor (normal-adjacent tissue) of cancer patients as a surrogate of pre-cancer tissue that are difficult to collect. There have been studies in identifying epigenetic field defects ([@B1]), notably early DNA methylation alterations. DNA methylation is an epigenetic modification that has been shown to be crucial in gene expression ([@B5]) and cancers ([@B9]). There are mainly two types of aberrant DNA methylation in cancers, local hyper-methylation in promoter-related CpGs that leads to the silencing of downstream tumor suppressor genes ([@B13]), and global hypo-methylation that leads to chromosome instability ([@B17]). Studies have successfully identified epigenetic field defects in breast cancer by comparing normal-adjacent tissue of breast cancer patients to normal tissue from healthy individuals. Teschendorff *et al.* identified epigenetic field defects in breast cancer based on differential variability (DV), i.e. variance signals in DNA methylation ([@B3]), using methylation site-level analyses. Our previous work ([@B21]) identified epigenetic field defects in breast cancer based on both differential methylation (DM), i.e. mean signals, and DV, using methylation region-level analyses. In both studies, epigenetic field defects were found to be mainly driven by increased variation in methylation due to several outlier normal-adjacent tissue samples.

Due to the fact that CpG site-level signals for epigenetic field defects may be very small, existing methods based on differences (DM or DV or both) on CpG site-level may not have good power. Standard epigenome-wide association studies (EWAS) that focus on mean signals (EWAS-DM) perform CpG site-level tests to identify differentially methylated CpGs between two experimental groups using standard tests such as a t-test, a regression-based test or its regularized versions ([@B22]), or a non-parametric Wilcoxon rank sum test ([@B25]). EWAS that focus on variance signals (EWAS-DV) perform CpG site-level tests to identify differential variation CpGs between two experimental groups using standard tests such as the F-test ([@B26],[@B27]), the Bartlett\'s test or its regularized version ([@B3],[@B4]), or an empirical Bayes extension of the Levene\'s test ([@B28]). The F-test and Bartlett\'s test are sensitive to departures from normality which is usually the case for methylation data, while the Levene\'s test is more robust to non-normality. On the other hand, distance-based methods that characterize (dis)similarity between pairwise samples across a gene, a genetic region, a pathway or an entire genome have been proven to be powerful in genetic and gene expression studies ([@B29]). While standard EWAS perform CpG site-level tests with stringent multiple comparisons adjustment, in a gene or a genetic region level, the common practice using non-distance-based methods is to select the minimum *P*-value out of all CpGs in that region. These methods will not be powerful when site-level effects are very small. Alternatively, the distance-based methods accumulate any CpG site-level signals from a gene or a genetic region via the (dis)similarity matrix thus boost the overall association power, making them the ideal methods for detection of epigenetic field defects.

Here, we developed a weighted epigenetic distance-based method to identify epigenetic field defects at gene or genetic-region levels using both DM and DV signals. CpG site-level weights were incorporated in the calculation of (dis)similarity matrix to further boost signals and reduce noises. Specifically, we used original DNA methylation measures to examine DM and centered quadratic methylation measures to examine DV and considered site-level weights based on strengths of site-level DM and DV signals. Simulation studies showed much improved performance of the proposed weighted epigenetic distance-based method over several comparing methods including non-weighted versions and methods that use either DM or DV signals as well as standard EWAS methods. We further demonstrated the performance of the proposed method through an application to the 450K DNA methylation data of normal-adjacent tissue of breast invasive carcinoma (BRCA) patients and normal tissue from independent age-matched cancer-free women from Gene Expression Omnibus (GEO). The proposed method that accumulates weighted DM and DV signals identified genes with epigenetic field defects that were missed by standard EWAS methods and non-weighted distance-based methods. Many of these epigenetic field defects were previously reported to be associated with breast cancer. Further examination confirmed their enrichment in the progression to breast cancer and replicated some of these identified epigenetic field defects.

MATERIALS AND METHODS {#SEC2}
=====================
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Step 1: Define gene-level weighted epigenetic distance matrix {#SEC2-1}
-------------------------------------------------------------
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### Incorporate CpG site-level weights into epigenetic distance matrix {#SEC2-1-2}
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Step 2: Calculate pseudo-*F* statistic {#SEC2-2}
--------------------------------------

We apply distance-based regression originally developed in the field of ecology ([@B31],[@B32]) to test if DNA methylation measures in a gene is associated with the case-control status. Specifically, for each gene, we calculate a pseudo-$\documentclass[12pt]{minimal}
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### Simulation settings with one gene {#SEC2-6-1}

We first considered one gene with different number of CpGs with different signal-to-noise ratios of the CpGs. That is, the ratio between number of signal CpGs and number of noise CpGs in this gene ranges from 1:0, 1:24, 1:49, 3:47, to 5:45. We considered scenarios when signal CpGs have different mean or variance signals by varying shape parameters $\documentclass[12pt]{minimal}
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### Simulation settings with 10 genes {#SEC2-6-2}

We then considered 10 genes with one gene having signals when there are 25 CpGs in each of the 10 genes. In the signal gene, we set one CpG to have mean or/and variance signals with different effect sizes. Here we test for the global null and consider a simulation study to be significant if any gene is significant after Bonferroni adjustment for testing 10 genes. The empirical *P*-value for each gene is calculated using formula 5, where *G* = 10.

### Simulation settings with outliers {#SEC2-6-3}

Since epigenetic field defects are often characterized by increased variation in DNA methylation due to a few outlier normal-adjacent tissue samples ([@B3],[@B21]), we considered simulation scenarios with outlier samples. Here, we only considered one gene with 50 CpGs for illustration purposes. We considered two signal-to-noise ratios in this gene to be either 5:45 or 10:40. We set 10%, 15% or 20% of cases to be outlier samples with DNA methylation alterations at some signal CpGs, while the rest cases have the same methylation measures as controls at those signal CpGs when different outlier samples could have DNA methylation alterations at different signal CpGs, For each signal CpG, we generated methylation measures $\documentclass[12pt]{minimal}
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### Simulation settings with one gene considering correlations among CpGs {#SEC2-6-4}

Since neighboring CpGs are known to be correlated, we considered simulation scenarios that assume an AR(1) correlation among CpGs in a gene with a correlation coefficient 0.5. The detailed information for simulation setup for this scenario is summarized in the [Supplementary File section 2](#sup1){ref-type="supplementary-material"} Simulation settings with one gene considering correlations among CpGs.

RESULTS {#SEC3}
=======

Simulation results {#SEC3-1}
------------------

### Type I error rate {#SEC3-1-1}

Type I error rates are well controlled at the 0.05 significance level in settings with one gene and 10 genes after Bonferroni adjustment for multiple comparisons (Table [1](#tbl1){ref-type="table"}), respectively.
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^a^Type I error rates after Bonferroni adjustment for 10 genes.
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### Power for simulation settings with one gene {#SEC3-1-2}

Power results for simulation settings with one gene are summarized in Figure [1](#F1){ref-type="fig"}. When there are only mean signals at signal CpGs, $\documentclass[12pt]{minimal}
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Similar power patterns are observed when signal CpGs are set to have variance signals only. $\documentclass[12pt]{minimal}
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### Power for simulation settings with 10 genes {#SEC3-1-3}

Power results for simulation settings with 10 genes are summarized in Figure [2](#F2){ref-type="fig"}. When signal CpGs have either mean or variance signals, we observed similar patterns as in the simulation settings with one gene. When signal CpGs have non-negligible mean signals and variance signals ranging from weak to strong, $\documentclass[12pt]{minimal}
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### Power for simulation settings with outliers {#SEC3-1-4}

Power results for simulation settings with outlier samples are summarized in Figure [3](#F3){ref-type="fig"}. We observe that power of all methods increases as the signal-to-noise ratio increases and as the proportion of outlier samples increases as expected, and distance-based methods outperform non-distance-based methods while $\documentclass[12pt]{minimal}
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![Power results for simulation settings with outlier samples. We set to have 10%, 15% and 20% outlier samples and two different signal-to-noise ratios 5:45 and 10:40.](gky882fig3){#F3}

### Power for simulation settings with one gene considering correlations among CpGs {#SEC3-1-5}

The type I error rates under this scenario are summarized in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}. The power results are summarized in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}. We note that the power patterns are very similar to those observed in simulations ignoring correlations among CpG sites. This implies that the correlations among neighboring CpGs do not have much impact on the performance of the proposed distance-based methods.

Real data application {#SEC3-2}
---------------------
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Discovery analysis using the GEO BRCA data {#SEC3-3}
------------------------------------------
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}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$ and the comparing methods to the GEO 450K DNA methylation data of normal-adjacent tissue of breast invasive carcinoma (BRCA) patients and normal tissue from independent age-matched cancer-free women (GSE69914). In the original GEO BRCA data, there are DNA methylation measures on 485,512 CpGs for 42 tumor and normal-adjacent pairs from breast cancer patients, 50 normal tissue of independent age-matched cancer-free women and 263 additional tumor tissue of independent breast cancer patients. We conducted standard quality control steps where we removed CpGs on sex chromosomes and those contain either a SNP at the CpG interrogation or at the single nucleotide extension (SBE) based on UCSC dbSNP table version 147 using the R package 'IlluminaHumanMethylation450kanno.ilmn12.hg19' ([@B35]). We also required at least 95% CpG coverage per sample and 70% sample coverage per CpG, and only kept CpGs with gene annotations. We ended up with 344 947 CpGs, covering 19 271 genes, from 42 normal-adjacent tissues, 50 normal tissues and 263 independent tumor tissues.

Since Bonferroni adjustment for multiple comparisons of the 19 271 genes is too conservative, especially with the small sample size in the GEO BRCA dataset, we used a less stringent threshold 0.0005 on empirical gene-level *P*-values obtained from the permutation procedure (Figure [4](#F4){ref-type="fig"}). Our main purpose is to demonstrate the superior performance of the proposed method $\documentclass[12pt]{minimal}
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  Rank   Gene           \# CpG   Cancer                            Rank in $\documentclass[12pt]{minimal}
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                                                                   }{}$EWA{S^{\min - P}}$\end{document}$
  ------ -------------- -------- --------------------------------- ----------------------------------------
  1      *TMC4\**       13       Breast Cancer ([@B37])            2
  2      *ZFP57*        5        Breast Cancer ([@B38])            16
  3      *DPH3B*        5        --                                61
  4      *NAA35\**      7        Breast Cancer ([@B39])            10
  5      *ANKRD13B*     22       Breast Cancer ([@B40])            25
  6      *PENK*         23       Breast Cancer ([@B41])            37
  7      *THY1\**       19       Breast Cancer ([@B42])            13
  8      *CXCL6\**      7        Breast Cancer ([@B43])            1
  9      *KDM5A\**      2        Breast Cancer ([@B44])            4
  10     *HBA1*         7        Breast Cancer ([@B45])            23
  11     *SPAG6*        16       Acute Myeloid Leukemia ([@B46])   170
  12     *AQP3*         7        Breast Cancer ([@B47])            140
  13     *TRH*          16       Breast Cancer ([@B48])            28
  14     *SLC7A4*       12       Breast Cancer ([@B49])            175
  15     *FKBP4\**      18       Breast Cancer ([@B50])            7
  16     *PRDM5*        18       Breast Cancer ([@B51])            36
  17     *MMP23B*       2        Breast Cancer ([@B52])            80
  18     *TMEFF1*       5        Breast Cancer ([@B53])            156
  19     *PRSS48*       7        --                                64
  20     *CFTR*         16       Breast Cancer ([@B54])            1055
  21     *TMEM200B\**   20       Breast Cancer ([@B55])            3
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  Rank   Gene           \# CpG   Top CpG Signal^a^   Cancer                              Rank in $\documentclass[12pt]{minimal}
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  ------ -------------- -------- ------------------- ----------------------------------- -----------------------------------------------
  1      *CXCL6\**      7        Variance            Breast Cancer ([@B43])              11
  2      *TMC4\**       13       Variance            Breast Cancer ([@B37])              1
  3      *TMEM200B\**   20       Variance            Acute Myeloid Leukemia ([@B56])     41
  4      *KDM5A\**      2        Variance            Breast Cancer ([@B44])              4
  5      *NRBP1*        12       Variance            Breast Cancer ([@B57])              110
  6      *SALL1*        44       Variance            Breast Cancer ([@B58])              887
  7      *FKBP4\**      18       Variance            Breast Cancer ([@B50])              32
  8      *NOL6*         5        Variance            \-                                  160
  9      *PLS1*         16       Variance            Bladder Cancer ([@B59])             1069
  10     *NAA35\**      7        Variance            Breast Cancer ([@B39])              6
  11     *ZNF132*       12       Mean                Prostate Cancer ([@B60])            118
  12     *STAU2*        39       Variance            Hepatocellular Carcinoma ([@B61])   666
  13     *THY1\**       19       Variance            Breast Cancer ([@B42])              14
  14     *FAM198B*      14       Variance            Breast Cancer ([@B62])              84

^a^Mean or variance tests with smaller *P*-value at the most significant CpG in a gene.
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We then investigated the two genes, *CFTR* and *PLS1*, that were uniquely identified by $\documentclass[12pt]{minimal}
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}{}$EWA{S^{\min - P}}$\end{document}$, respectively, but ranked the last using the other method among all uniquely identified genes. We similarly plotted the heatmap of the original DNA methylation measures of CpG sites in these two genes (Figure [5A](#F5){ref-type="fig"}). For the *CFTR* gene that has 16 CpGs, it is clear that variation in methylation measures increases in the progression from normal tissues to normal-adjacent tissues and to tumor tissues in multiple CpGs when there are several samples among the 42 normal-adjacent tissue samples that are very different from the normal samples. On the other hand, for the *PLS1* gene that also has 16 CpGs, it was identified uniquely by $\documentclass[12pt]{minimal}
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}{}$EWA{S^{\min - P}}$\end{document}$ because of one signal CpG site cg00137209 (Figure [5A](#F5){ref-type="fig"}), mainly due to the very small variation in the methylation measures of the normal tissues. We then plotted DNA methylation measures of the top 4 *P*-value ranked CpGs, ranked by CpG site-level *P*-values from both mean and variance tests each after adjusting for multiple comparisons for the number of CpGs in the *CFTR* gene (Figure [5B](#F5){ref-type="fig"}), which clearly shows elevated methylation levels in the progression to tumor. For the *PLS1* gene, we similarly plotted the DNA methylation measures of the top 2 *P*-value ranked CpGs (Figure [5B](#F5){ref-type="fig"}), where the \#1 ranked CpG cg00137209 is the one that shows strong variance signal due to very small variation in the methylation measures of the normal tissues, when neither CpGs showed any enrichment in methylation measures in the progression to tumor. This suggests that genes uniquely identified by $\documentclass[12pt]{minimal}
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![(**A**) Heatmaps of DNA methylation measures of CpGs in the *CFTR* and *PLS1* genes. The CpGs underlined are the top 4 *P*-value ranked CpGs in the *CFTR* gene and the top 2 *P*-value ranked CpGs in the *PLS1* gene. (**B**) DNA methylation measures of 50 normal tissues, 42 normal-adjacent tissues and 42 matched tumors of the top 4 *P*-value ranked CpGs in the *CFTR* gene and the top 2 *P*-value ranked CpGs in the *PLS1* gene. Pm and Pv are *P*-values from CpG site-level mean and variance tests adjusted for multiple comparisons for the number of CpGs in the gene. The three horizontal lines represent mean methylation levels of the three groups of normal tissues, normal-adjacent tissues and matched tumors.](gky882fig5){#F5}

We also plotted the DNA methylation measures of all CpGs in these two genes *CFTR* and *PLS1* ([Supplementary Figures S5 and S6](#sup1){ref-type="supplementary-material"}, respectively). It is again clear that almost half of the CpGs in the *CFTR* gene have weak mean signals and weak variance signals, thus missed by $\documentclass[12pt]{minimal}
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}{}$EWA{S^{\min - P}}$\end{document}$ due to stringent multiple comparisons adjustment. In addition, we plotted the weighted distance matrices of the 50 normal tissues and the 42 normal-adjacent tissues for the *CFTR* gene and the *PLS1* gene ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). For the *CFTR* gene, we observe little variation in distances among normal samples and increased variation in distances between several pairs of normal and normal-adjacent samples, while for the *PLS1* gene, we observe no clear pattern. We also plotted the DNA methylation measures of CpGs in the *TMC4* gene ([Supplementary Figure S8](#sup1){ref-type="supplementary-material"}) that was identified by both $\documentclass[12pt]{minimal}
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\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$ and $\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$EWA{S^{\min - P}}$\end{document}$.

In our previous work on differentially methylated regions (DMRs) using the same GEO BRCA data, we identified 2 DMRs of epigenetic field defects using both mean and variance signals ([@B21]). The two DMRs cover two genes, *NKX6−2* and *CCND2*, which rank \#113 and \#359 in the $\documentclass[12pt]{minimal}
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}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$ across the whole genome. The rank of the *NKX6−2* part that matches with the DMR moved up to \#90 from \#113 while the other two parts rank \#107 and \#4855, respectively. The rank of the *CCND2* part that matches with the other DMR moved up to \#154 from \#359 and the other part ranks \#1116. Overall, the 2 DMR-covered genes previously identified as epigenetic field defects also rank on top in the results of $\documentclass[12pt]{minimal}
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We also investigated the relation between the number of CpGs in a gene and the probability that the gene is selected, where we binned genes based on their sizes and calculated the selection probability of a gene in a bin as the proportion of genes identified out of all genes in the bin. We plotted the selection probabilities against gene sizes ([Supplementary Figure S9](#sup1){ref-type="supplementary-material"}) and found that the selection probabilities for different versions of the distance-based methods and $\documentclass[12pt]{minimal}
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Validation of the identified epigenetic field defects in the GEO BRCA data {#SEC3-4}
--------------------------------------------------------------------------

We further validated the 21 genes of epigenetic field defects identified by $\documentclass[12pt]{minimal}
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}{}$ - {\log _{10}}(p{\rm{ - value}})$\end{document}$ from the two comparisons, 50 normal tissues versus 42 normal-adjacent tissues and 42 normal-adjacent tissues vs. 263 tumor tissues ([Supplementary Figure S10](#sup1){ref-type="supplementary-material"}). In general, the majority of these CpGs show more significant signals in the progression from normal tissues to normal-adjacent tissues to tumor.

Replication analysis using an independent data of normal tissues {#SEC3-5}
----------------------------------------------------------------

As epigenetic field defects identified in one set of normal vs. normal-adjacent comparison maybe driven by a few 'outlier' normal-adjacent samples ([@B3],[@B4],[@B21]), different epigenetic field defects could be identified in a different set of normal versus normal-adjacent comparison that are driven by different 'outlier' normal-adjacent samples. Therefore, we propose to conduct a replication analysis that uses the same normal-adjacent tissue samples but compare to an independent data of normal samples. We used 450K DNA methylation data of 18 normal tissue of 18 breast reduction mammoplasty subjects (GSE67919) ([@B36]). The original data have methylation measures on 485 577 CpG sites. We followed the same quality control steps as for the discovery GEO BRCA data (GSE69914) and kept the same CpG sites for comparison purposes. We ended up with 344 947 CpGs, covering 19 271 genes, from 18 normal tissues. We then compared these normal samples to the same 42 normal-adjacent tissues from the GEO BRCA data in a replication analysis.

At the same 0.0005 threshold for gene-level *P*-values, 7 out of the 21 previously identified genes with epigenetic field defects in the discovery analysis using the GEO BRCA data were replicated by $\documentclass[12pt]{minimal}
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}{}$t$\end{document}$-tests comparing the 42 GEO BRCA normal-adjacent samples to the 263 independent GEO BRCA tumor samples ([Supplementary Figure S11](#sup1){ref-type="supplementary-material"}). All 7 genes, except the *NAA35* and *FKBP4*, exhibit progression to tumor. More details of the replication analysis results using $\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$, $\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$EWA{S^{\min - P}}$\end{document}$ and other comparing distance-based methods were summarized in [Supplementary File section 3.3](#sup1){ref-type="supplementary-material"} Replication Analysis and [Supplementary Table S8](#sup1){ref-type="supplementary-material"} and [Supplementary Figures S12--S14](#sup1){ref-type="supplementary-material"}.

To investigate our hypothesis that different epigenetic field defects maybe identified when comparing normal samples to a different set of normal-adjacent samples, we obtained a new set of BRCA normal-adjacent samples (n = 90) from the Cancer Genome Atlas (TCGA) project together with their matched tumor samples (*n* = 90). We plotted DNA methylation measures of CpGs in the 7 replicated genes ([Supplementary File 2](#sup1){ref-type="supplementary-material"}) of the 18 replication normal samples, the 50 discovery GEO BRCA normal samples, the 42 discovery GEO BRCA normal-adjacent samples, the 42 discovery GEO BRCA matched tumor samples, and the 90 TCGA normal-adjacent samples and the 90 TCGA matched tumor samples. It is clear that methylation patterns of the TCGA normal-adjacent tissues are very different from that of the discovery GEO BRCA normal-adjacent tissues in most of these CpGs. This supports our hypothesis that methylation patterns can be very different in different pre-cancer tissues (using normal-adjacent tissue as a surrogate) thus different epigenetic field defects maybe identified when normal samples are compared to different sets of pre-cancer tissues.

DISCUSSION {#SEC4}
==========

In this study, we developed a weighted epigenetic distance-based method $\documentclass[12pt]{minimal}
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}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$, we used CpG site-level association strengths as weights for individual CpGs aiming to up-weight signal CpGs and down-weight noise CpGs. If the feature preselection step could be conducted perfectly, it is equivalent to the case when weight '0' is correctly assigned to noise CpGs and weight '1' is correctly assigned to signal CpGs. Results from simulation studies suggest that when the signal-to-noise ratio in a gene decreases, power of non-weighted epigenetic distance-based methods decreased drastically, while power of the weighted version was well maintained. This suggests that incorporating CpG-site-level association strengths as weights for individual CpGs indeed help to up-weight signal CpGs and down-weight noise CpGs, thus improve the overall study performance. Simulation results also suggest that the weighted epigenetic distance-based methods will be most effective when applied to genes or genetic regions with a small percentage of CpGs having weak signals. This makes the detection of epigenetic field defects, i.e., early epigenetic alterations that are usually infrequent across samples and identifiable as outlier samples, the ideal application of the proposed method $\documentclass[12pt]{minimal}
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}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$ results except for the *PLS1* gene. However, further investigations suggested that the *PLS1* gene may not be a real epigenetic field defect. On the other hand, most of the genes uniquely identified by $\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$ also ranked on top in the $\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$EWA{S^{\min - P}}$\end{document}$ results except for the *CFTR* gene, in which the enrichment in the progression to breast cancer was confirmed in further analyses. This suggests that genes identified by $\documentclass[12pt]{minimal}
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}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$, which are generally characterized by multiple signal CpGs, are more reliable. It is worth noticing that the 2 DMR-covered genes identified in our previous work ([@B21]) also ranked on top in the $\documentclass[12pt]{minimal}
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In general, distance-based methods have a better performance than that of site-level EWAS methods when site-level signals are weak. As discussed in our previous work ([@B21]) and work of others ([@B3],[@B4]), epigenetic field defects are often characterized by increased variation in DNA methylation measures due to a few outlier normal-adjacent tissue samples. So the site-level EWAS methods are usually underpowered due to small mean differences as well as stringent multiple comparisons adjustment. Distance-based methods accumulate weak signals to improve power. Distance-based methods are flexible and can be applied to a CpG site, a gene, a pathway, or an entire genome. A closer investigation on what we identified in our previous work ([@B21]) in DMR detection and the current work suggests that we may take advantages of the techniques in DMR detection and combine that with distance-based methods in future works to more efficiently identify regions of epigenetic field defects.

In summary, we proposed a new weighted distance-based method $\documentclass[12pt]{minimal}
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}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$ that considers both DM and DV in DNA methylation and incorporates site-level association strengths as weights on individual CpGs to up-weight signal CpGs and down-weight noise CpGs to further boost the overall study power. The $\documentclass[12pt]{minimal}
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}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$ method is especially powerful in detecting epigenetic field defects when methylation alterations between normal tissues and normal-adjacent tissues are usually minimum.

DATA AVAILABILITY {#SEC5}
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An R code for the proposed method $\documentclass[12pt]{minimal}
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}{}${{{\bf D}}^{w - DM - DV}}$\end{document}$ together with a tutorial and a sample data set is available for downloading from [http://www.columbia.edu/∼sw2206/softwares.htm](http://www.columbia.edu/~sw2206/softwares.htm).

The BRCA 450K DNA methylation data of 50 normal tissues, 42 normal tissues adjacent to tumors together with 42 matched tumor tissues, and 263 independent tumor tissues were downloaded from Gene Expression Omnibus (GEO) under the accession number GSE69914. The 450K DNA methylation data of 18 normal tissue of 18 breast reduction mammoplasty subjects were downloaded from Gene Expression Omnibus (GEO) under the accession number GSE67919. The 450K DNA methylation data of 90 BRCA normal-adjacent and tumor pairs were downloaded from the Cancer Genome Atlas (TCGA) project.
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Click here for additional data file.
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[Supplementary Data](https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gky882#supplementary-data) are available at NAR Online.
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